You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer

Article info

Article menu
Oncolytic and local immunotherapy
Original research
Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer

Authors

  • Ilkka Liikanen Division of Biological Sciences, Section of Molecular Biology, University of California San Diego, San Diego, California, USADepartment of Oncology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Saru Basnet Translational Immunology Research Program, Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Dafne C A Quixabeira Translational Immunology Research Program, Cancer Gene Therapy Group, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Kristian Taipale Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Otto Hemminki Division of Urologic Oncology, Department of Surgical Oncology, University of Toronto, Toronto, Ontario, CanadaDepartment of Urology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Minna Oksanen Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Matti Kankainen Medical and Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, FinlandTranslational Immunology Research Program and Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Juuso Juhila Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Anna Kanerva Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandDepartment of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Timo Joensuu Docrates Cancer Hospital, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Siri Tähtinen Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Akseli Hemminki Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki, FinlandCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandTILT Biotherapeutics Ltd, Helsinki, Finland PubMed articlesGoogle scholar articles

Citation

Liikanen I, Basnet S, Quixabeira DCA, et al
Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer
Journal for ImmunoTherapy of Cancer 2022;10:e003490. doi: 10.1136/jitc-2021-003490
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.